Targeted therapy for metastatic renal cell carcinoma

被引：133

作者：

Patel, PH

Chaganti, RSK

Motzer, RJ

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA

[2] Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA

来源：

BRITISH JOURNAL OF CANCER | 2006年 / 94卷 / 05期

关键词：

von Hippel -Lindau; sunitinib; sorafenib; CCI-779; bevacizumab; erlotinib;

D O I：

10.1038/sj.bjc.6602978

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Metastatic renal cell carcinoma ( RCC) has historically been refractory to cytotoxic and hormonal agents; only interleukin 2 and interferon alpha provide response in a minority of patients. We reviewed RCC biology and explored the ways in which this understanding led to development of novel, effective targeted therapies. Small molecule tyrosine kinase inhibitors, monoclonal antibodies and novel agents are all being studied, and phase II studies show promising activity of sunitinib, sorafenib and bevacizumab. The results of phase III studies will determine the role of these agents in metastatic RCC.

引用

页码：614 / 619

页数：6

共 37 条

[1] Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma [J].

Atkins, MB ;

Hidalgo, M ;

Stadler, WM ;

Logan, TF ;

Dutcher, JP ;

Hudes, GR ;

Park, Y ;

Lion, SH ;

Marshall, B ;

Boni, JP ;

Dukart, G ;

Sherman, ML .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :909-918

[2] Hypoxia-inducible factor-1 and oncogenic signalling [J].

Bárdos, JI ;

Athcroft, M .

BIOESSAYS, 2004, 26 (03) :262-269

[3] Rising incidence of renal cell cancer in the United States [J].

Chow, WH ;

Devesa, SS ;

Warren, JL ;

Fraumeni, JF .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (17) :1628-1631

[4]

ESCUDIER B, 2005, J CIN ONCOL

[5] A small molecule-kinase interaction map for clinical kinase inhibitors [J].

Fabian, MA ;

Biggs, WH ;

Treiber, DK ;

Atteridge, CE ;

Azimioara, MD ;

Benedetti, MG ;

Carter, TA ;

Ciceri, P ;

Edeen, PT ;

Floyd, M ;

Ford, JM ;

Galvin, M ;

Gerlach, JL ;

Grotzfeld, RM ;

Herrgard, S ;

Insko, DE ;

Insko, MA ;

Lai, AG ;

Lélias, JM ;

Mehta, SA ;

Milanov, ZV ;

Velasco, AM ;

Wodicka, LM ;

Patel, HK ;

Zarrinkar, PP ;

Lockhart, DJ .

NATURE BIOTECHNOLOGY, 2005, 23 (03) :329-336

[6] Mechanisms of disease: Rules for making human tumor cells. [J].

Hahn, WC ;

Weinberg, RA .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (20) :1593-1603

[7] Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib [J].

Hainsworth, JD ;

Sosman, JA ;

Spigel, DR ;

Edwards, DL ;

Baughman, C ;

Greco, A .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (31) :7889-7896

[8] SILENCING OF THE VHL TUMOR-SUPPRESSOR GENE BY DNA METHYLATION IN RENAL-CARCINOMA [J].

HERMAN, JG ;

LATIF, F ;

WENG, YK ;

LERMAN, MI ;

ZBAR, B ;

LIU, S ;

SAMID, D ;

DUAN, DSR ;

GNARRA, JR ;

LINEHAN, WM ;

BAYLIN, SB .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (21) :9700-9704

[9] Structural basis for the recognition of hydroxyproline in αIF-1α by pVHL [J].

Hon, WC ;

Wilson, MI ;

Harlos, K ;

Claridge, TDW ;

Schofield, CJ ;

Pugh, CW ;

Maxwell, PH ;

Ratcliffe, PJ ;

Stuart, DI ;

Jones, EY .

NATURE, 2002, 417 (6892) :975-978

[10] Activation of HIF1α ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex [J].

Kamura, T ;

Sato, S ;

Iwai, K ;

Czyzyk-Krzeska, M ;

Conaway, RC ;

Conaway, JW .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (19) :10430-10435

← 1 2 3 4 →